Just how sadly misguided is the FDA on aducanumab?
I doubt very much that Biogen paid anyone at the FDA to get an approval on aducanumab with this generous (?) label. But if they had, I doubt that even the execs at Biogen would have asked for this much.
Cheating requires some caution, if you expect to get away with it. And this one goes way past a cautious manipulation of regulatory powers in accomplishing a megablockbuster company goal worth potentially tens of billions of dollars.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 163,900+ biopharma pros reading Endpoints daily — and it's free.